HALO
Price
$75.85
Change
+$0.92 (+1.23%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
8.76B
63 days until earnings call
IDYA
Price
$23.39
Change
-$3.77 (-13.88%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
2.38B
64 days until earnings call
Interact to see
Advertisement

HALO vs IDYA

Header iconHALO vs IDYA Comparison
Open Charts HALO vs IDYABanner chart's image
Halozyme Therapeutics
Price$75.85
Change+$0.92 (+1.23%)
Volume$28.82K
Capitalization8.76B
IDEAYA Biosciences
Price$23.39
Change-$3.77 (-13.88%)
Volume$36.91K
Capitalization2.38B
HALO vs IDYA Comparison Chart in %
Loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. IDYA commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Buy and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (HALO: $74.93 vs. IDYA: $27.16)
Brand notoriety: HALO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 105% vs. IDYA: 163%
Market capitalization -- HALO: $8.76B vs. IDYA: $2.38B
HALO [@Biotechnology] is valued at $8.76B. IDYA’s [@Biotechnology] market capitalization is $2.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 2 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 2 green, 3 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 5 bullish TA indicator(s).

  • HALO’s TA Score: 3 bullish, 3 bearish.
  • IDYA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than HALO.

Price Growth

HALO (@Biotechnology) experienced а +2.43% price change this week, while IDYA (@Biotechnology) price change was +10.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.13%. For the same industry, the average monthly price growth was +10.99%, and the average quarterly price growth was +33.00%.

Reported Earning Dates

HALO is expected to report earnings on Nov 10, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($8.76B) has a higher market cap than IDYA($2.38B). HALO YTD gains are higher at: 56.725 vs. IDYA (5.681). HALO has higher annual earnings (EBITDA): 792M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. HALO (548M). IDYA has less debt than HALO: IDYA (26.6M) vs HALO (1.51B). HALO has higher revenues than IDYA: HALO (1.18B) vs IDYA (7M).
HALOIDYAHALO / IDYA
Capitalization8.76B2.38B368%
EBITDA792M-380.2M-208%
Gain YTD56.7255.681999%
P/E Ratio17.15N/A-
Revenue1.18B7M16,843%
Total Cash548M670M82%
Total Debt1.51B26.6M5,673%
FUNDAMENTALS RATINGS
HALO vs IDYA: Fundamental Ratings
HALO
IDYA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
2968
SMR RATING
1..100
1197
PRICE GROWTH RATING
1..100
4043
P/E GROWTH RATING
1..100
84100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (63) in the null industry is in the same range as HALO (80) in the Biotechnology industry. This means that IDYA’s stock grew similarly to HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (29) in the Biotechnology industry is somewhat better than the same rating for IDYA (68) in the null industry. This means that HALO’s stock grew somewhat faster than IDYA’s over the last 12 months.

HALO's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for IDYA (97) in the null industry. This means that HALO’s stock grew significantly faster than IDYA’s over the last 12 months.

HALO's Price Growth Rating (40) in the Biotechnology industry is in the same range as IDYA (43) in the null industry. This means that HALO’s stock grew similarly to IDYA’s over the last 12 months.

HALO's P/E Growth Rating (84) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that HALO’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOIDYA
RSI
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
84%
Momentum
ODDS (%)
N/A
Bullish Trend 4 days ago
79%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
N/A
Bearish Trend 11 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
76%
Aroon
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IVOV101.930.42
+0.41%
Vanguard S&P Mid-Cap 400 Value ETF
UMAY35.630.02
+0.05%
Innovator U.S. Equity Ultra BffrETF™-May
LFAL137.04N/A
N/A
LifeX 2053 Longevity Income ETF
EMTY11.40-0.03
-0.25%
ProShares Decline of the Retl Store ETF
AVMV69.48-0.23
-0.33%
Avantis U.S. Mid Cap Value ETF

HALO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with XENE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
+2.08%
XENE - HALO
45%
Loosely correlated
+1.48%
IRON - HALO
37%
Loosely correlated
+0.95%
IDYA - HALO
35%
Loosely correlated
+5.15%
NGNE - HALO
35%
Loosely correlated
+1.73%
TECH - HALO
35%
Loosely correlated
+2.82%
More